Precision Olfactory Delivery (POD®) of Drugs for Neurological Disease: A Safety, Tolerability and Comparative Bioavailability Study of POD Dihydroergotamine Mesylate (INP104) to Approved IV D.H.E. 45® and Migranal® Nasal Spray. (P2.10-022)
Year: 2019
Type: article
Source: Neurology
Institution: Impel Neuropharma (United States)
Language: English
Subfield: Pharmaceutical Science
Domain: Life Sciences
Open Access status: closed
OpenAlex ID: W3156237928
